Relapsed Acute Myeloid Leukemia Clinical Trials

20 clinical trials for Relapsed Acute Myeloid Leukemia across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia — RECRUITING · PHASE1
• CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML — RECRUITING · PHASE1
• A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia — RECRUITING · PHASE1
• Imetelstat Combinations in Relapsed AML — RECRUITING · PHASE1
• Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms — RECRUITING · PHASE1
• Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML — RECRUITING · PHASE1
• Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML — RECRUITING · PHASE2
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS — RECRUITING · PHASE2
• Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS — ACTIVE_NOT_RECRUITING · PHASE1
• FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) — TERMINATED · PHASE2
• A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) — TERMINATED · PHASE1
• Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML — WITHDRAWN · PHASE2
• Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia — COMPLETED · PHASE1
• Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML — COMPLETED
• Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia — OTHER · PHASE2
• A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome — COMPLETED · PHASE1
• Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS — WITHDRAWN · PHASE2
• Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML — TERMINATED · PHASE1
• Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1

Refine this search